Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update

    NEXT STORY
    Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results
    PREV STORY
    Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

    NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (OTCQX:CKPT), a ...

    author_avatar
    NASDAQ Market News

    ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock

    author_avatar
    NASDAQ Market News

    ADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

    author_avatar
    NASDAQ Market News